Search
The Kids Research Institute Australia, Perth Children’s Hospital Foundation and Perth Children’s Hospital have formed a strategic partnership to support the establishment and operation of the Wal-yan Respiratory Research Centre.
The Wal-yan Respiratory Research Centre is made up of multi-disciplinary teams that are committed to improving the lives of children and their families living with respiratory disease.
The AERIAL study, in partnership with The ORIGINS Project, endeavours to understand if exposures during pregnancy and early life can affect the cells lining the airways in newborns, and whether this is associated with the development of wheeze, allergy and asthma later in childhood.
Find out how you can get involved with our work at Phage WA.
Here are some of the most common questions about phage, phage therapy and antimicrobial resistance (AMR).
Learn more about all of the Clinical Trials, Platforms & Cohorts at the Wal-yan respiratory centre.
Cystic fibrosis (CF) is the most common life‐shortening genetic disease affecting children.
Nontypeable Haemophilus influenzae (NTHi) is a major otitis media (OM) pathogen, with colonization a prerequisite for disease development. Most acute OM is in children <5 years old, with recurrent and chronic OM impacting hearing and learning. Therapies to prevent NTHi colonization and/or disease are needed, especially for young children. Respiratory viruses are implicated in driving the development of bacterial OM in children.
Researchers from The Kids Research Institute Australia have been awarded more than $11 million to support vital child health projects, under the Federal Government’s Medical Research Future Fund.
COMBAT CF is one of two long-standing international trials which have resulted in new early intervention options helping to reduce progressive lung damage in kids living with CF.